ZF2001疫苗在预防2019年冠状病毒病(COVID-19)方面表现出很高的疗效。然而,接种疫苗者突破性感染的临床特征和COVID-19患者不良结局的危险因素仍不清楚.我们在中南大学湘雅医院进行了一项回顾性单中心队列研究,包括2022年12月5日至2023年1月31日期间210名完全接种COVID-19的住院患者。临床特征数据,实验室发现,疾病严重程度,治疗,收集并分析预后。我们的发现显示,COVID-19住院患者在发病时仍然会出现常见症状,但是大多数实验室发现都在正常范围内,除了白细胞计数(WBC),淋巴细胞计数,和乳酸脱氢酶(LDH)水平。在标准治疗之后,95.7%的患者出院。我们确定了七个变量与较高的不良结局风险显着相关,包括65岁以上白细胞计数升高,淋巴细胞计数减少,血尿素氮(BUN)水平较高,LDH,肌钙蛋白,D-二聚体,和降钙素原.这项研究支持ZF2001疫苗对COVID-19患者的实质性临床益处。此外,65岁以上,白细胞计数升高,淋巴细胞计数减少,和更高的血尿素氮水平,LDH,D-二聚体,和降钙素原可作为完全接种COVID-19的住院患者疾病进展的预测因子。
The ZF2001 vaccine has demonstrated high efficacy in preventing coronavirus disease 2019 (COVID-19). However, the clinical characteristics of breakthrough infections in vaccinated individuals and the risk factors for adverse outcomes in COVID-19 patients remain unclear. We conducted a retrospective single-center cohort study at Xiangya Hospital of Central South University, including 210 fully vaccinated COVID-19 inpatients from December 5, 2022, to January 31, 2023. Data on clinical characteristics, laboratory findings, disease severity, treatment, and prognosis were collected and analyzed. Our findings revealed that COVID-19 inpatients still experienced common symptoms at the onset of illness, but most laboratory findings were within the normal range, except for white blood cell count (WBC), lymphocyte count, and lactate dehydrogenase (LDH) levels. Following standard treatment, 95.7% of patients were discharged from the hospital. We identified seven variables significantly associated with a higher risk of adverse outcomes, including age over 65, elevated WBC count, reduced lymphocyte count, higher levels of blood urea nitrogen (BUN), LDH, troponin, D-dimer, and procalcitonin. This study supports the substantial clinical benefits of the ZF2001 vaccine for COVID-19 patients. Additionally, age over 65, elevated WBC count, reduced lymphocyte count, and higher blood levels of BUN, LDH, D-dimer, and procalcitonin may be used as predictive factors for disease progression in fully vaccinated COVID-19 inpatients.